United Therapeutics share price today

(UTHR)

United Therapeutics share price is $362.16 & -₹362.16 as on 12 Dec 2024, 2.30 'hrs' IST

$362.16

▲

-0.08

(-0.02%)

Market is closed - opens 8 PM, 12 Dec 2024

View live United Therapeutics share price in Dollar and Rupees. Guide to invest in United Therapeutics from India. Also see the sentimental analysis on Indian investors investing in United Therapeutics. Get details on the Indian mutual funds that are investing in United Therapeutics. Get Analyst recommendations and forecasts along with all the United Therapeutics's financials.

United Therapeutics share price movements

$360.59
$366.07
$362.16
0.43%
Downside
Day's Volatility :1.5%
Upside
1.07%
$208.62
$417.82
$362.16
42.39%
Downside
52 Weeks Volatility :50.07%
Upside
13.32%

United Therapeutics Returns

Period	United Therapeutics Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	6.17%	-8.8%	0.0%
6 Months	25.93%	-2.7%	0.0%
1 Year	40.95%	6.5%	0.0%
3 Years	89.4%	5.6%	-20.0%

United Therapeutics Key Statistics

in dollars & INR

Previous Close	$362.24
Open	$363.51
Today's High	$366.07
Today's Low	$360.5939
Market Capitalization	$16.2B
Today's Volume	$250.5K
52 Week High	$417.815
52 Week Low	$208.6249
Revenue TTM	$2.8B
EBITDA	$1.4B
Earnings Per Share (EPS)	$22.75
PE Ratio	15.92
Profit Margin	40.31%
Quarterly Earnings Growth YOY	0.19%
Return On Equity TTM	18.81%

How to invest in United Therapeutics from India?

It is very easy for Indian residents to invest directly in United Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the United Therapeutics stock in both rupees (INR) and dollars (USD). Search for United Therapeutics or UTHR on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of United Therapeutics or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of United Therapeutics shares which would translate to -0.000 fractional shares of United Therapeutics as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards United Therapeutics

-77%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for United Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 12, 2024. -77% less investors are searching United Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in United Therapeutics

BlackRock Inc
12.25%
Vanguard Group Inc
9.88%
Wellington Management Company LLP
7.10%
venBio Select Advisor LLC
6.40%
State Street Corp
5.01%
Renaissance Technologies Corp
4.83%

Analyst Recommendation on United Therapeutics

Buy

81%Buy

13%Hold

4%Sell

Based on 22 Wall street analysts offering stock ratings for United Therapeutics(by analysts ranked 0 to 5 stars)

Based on 22 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on United Therapeutics

What analysts predicted

Upside of 5.54%

Current:

$362.16

Target:

$382.22

Insights on United Therapeutics

Price Movement
In the last 3 years, UTHR stock has moved up by 92.1%
Increasing Revenue
Revenue is up for the last 8 quarters, 491.5M → 748.9M (in $), with an average increase of 5.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 278.1M → 309.1M (in $), with an average increase of 10.0% per quarter
UTHR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 46.2% return, outperforming this stock by 2.3%
Price to Sales
ForUTHR every $1 of sales, investors are willing to pay $6.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $15.4 for every $1 of sales.

United Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.6B	↓ 5.65%
Net Income	$589.2M	↑ 40.99%
Net Profit Margin	36.2%	↑ 11.98%

	FY19	Y/Y Change
Revenue	$1.4B	↓ 11.0%
Net Income	$-104.5M	↓ 117.74%
Net Profit Margin	-7.21%	↓ 43.41%

	FY20	Y/Y Change
Revenue	$1.5B	↑ 2.38%
Net Income	$514.8M	↓ 592.63%
Net Profit Margin	34.71%	↑ 41.92%

	FY21	Y/Y Change
Revenue	$1.7B	↑ 13.63%
Net Income	$475.8M	↓ 7.58%
Net Profit Margin	28.23%	↓ 6.48%

	FY22	Y/Y Change
Revenue	$1.9B	↑ 14.88%
Net Income	$727.3M	↑ 52.86%
Net Profit Margin	37.56%	↑ 9.33%

	FY23	Y/Y Change
Revenue	$2.3B	↑ 20.2%
Net Income	$984.8M	↑ 35.4%
Net Profit Margin	42.31%	↑ 4.75%

	Q2 FY23	Q/Q Change
Revenue	$596.5M	↑ 17.68%
Net Income	$259.2M	↑ 7.6%
Net Profit Margin	43.45%	↓ 4.07%

	Q3 FY23	Q/Q Change
Revenue	$609.4M	↑ 2.16%
Net Income	$267.6M	↑ 3.24%
Net Profit Margin	43.91%	↑ 0.46%

	Q4 FY23	Q/Q Change
Revenue	$614.7M	↑ 0.87%
Net Income	$217.1M	↓ 18.87%
Net Profit Margin	35.32%	↓ 8.59%

	Q1 FY24	Q/Q Change
Revenue	$677.7M	↑ 10.25%
Net Income	$306.6M	↑ 41.23%
Net Profit Margin	45.24%	↑ 9.92%

	Q2 FY24	Q/Q Change
Revenue	$714.9M	↑ 5.49%
Net Income	$278.1M	↓ 9.3%
Net Profit Margin	38.9%	↓ 6.34%

	Q3 FY24	Q/Q Change
Revenue	$748.9M	↑ 4.76%
Net Income	$309.1M	↑ 11.15%
Net Profit Margin	41.27%	↑ 2.37%

	FY18	Y/Y Change
Total Assets	$3.4B	↑ 18.11%
Total Liabilities	$612.4M	↓ 21.24%

	FY19	Y/Y Change
Total Assets	$3.9B	↑ 15.07%
Total Liabilities	$1.1B	↑ 85.01%

	FY20	Y/Y Change
Total Assets	$4.6B	↑ 17.93%
Total Liabilities	$1.2B	↑ 7.66%

	FY21	Y/Y Change
Total Assets	$5.2B	↑ 12.01%
Total Liabilities	$1.2B	↓ 0.79%

	FY22	Y/Y Change
Total Assets	$6.0B	↑ 16.94%
Total Liabilities	$1.2B	↑ 3.11%

	FY23	Y/Y Change
Total Assets	$7.2B	↑ 18.57%
Total Liabilities	$1.2B	↓ 5.26%

	Q2 FY23	Q/Q Change
Total Assets	$6.7B	↑ 5.28%
Total Liabilities	$1.3B	↑ 3.88%

	Q3 FY23	Q/Q Change
Total Assets	$7.0B	↑ 5.12%
Total Liabilities	$1.3B	↑ 3.24%

	Q4 FY23	Q/Q Change
Total Assets	$7.2B	↑ 2.04%
Total Liabilities	$1.2B	↓ 9.86%

	Q1 FY24	Q/Q Change
Total Assets	$6.5B	↓ 9.37%
Total Liabilities	$1.2B	↓ 2.12%

	Q2 FY24	Q/Q Change
Total Assets	$6.7B	↑ 3.51%
Total Liabilities	$1.0B	↓ 11.33%

	Q3 FY24	Q/Q Change
Total Assets	$7.1B	↑ 5.95%
Total Liabilities	$1.0B	↓ 0.37%

	FY18	Y/Y Change
Operating Cash Flow	$778.4M	↑ 64.15%
Investing Cash Flow	$-820.6M	↓ 1.8%
Financing Cash Flow	$6.3M	↓ 85.45%

	FY19	Y/Y Change
Operating Cash Flow	$-206.6M	↓ 126.54%
Investing Cash Flow	$-335.4M	↓ 59.13%
Financing Cash Flow	$611.2M	↑ 9601.59%

	FY20	Y/Y Change
Operating Cash Flow	$755.7M	↓ 465.78%
Investing Cash Flow	$-738.5M	↑ 120.18%
Financing Cash Flow	$-16.9M	↓ 102.77%

	FY21	Y/Y Change
Operating Cash Flow	$598.2M	↓ 20.84%
Investing Cash Flow	$-486.9M	↓ 34.07%
Financing Cash Flow	$44.8M	↓ 365.09%

	FY22	Y/Y Change
Operating Cash Flow	$802.5M	↑ 34.15%
Investing Cash Flow	$-811.5M	↑ 66.67%
Financing Cash Flow	$75.4M	↑ 68.3%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$106.3M	↓ 71.64%
Investing Cash Flow	$-227.2M	↑ 2.76%
Financing Cash Flow	$24.7M	↓ 49.18%

United Therapeutics Technicals Summary

Sell

Neutral

Buy

United Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

United Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
United Therapeutics Corporation	-9.66%	25.93%	40.95%	89.4%	103.67%
Regeneron Pharmaceuticals, Inc.	-5.85%	-24.7%	-11.77%	17.09%	105.58%
Biontech Se	12.25%	24.31%	22.8%	-57.11%	240.97%
Alnylam Pharmaceuticals, Inc.	-5.5%	58.79%	40.79%	36.33%	111.58%
Vertex Pharmaceuticals Incorporated	-4.43%	-2.24%	15.61%	124.98%	113.34%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
United Therapeutics Corporation	15.92	15.92	1.56	24.51	0.19	0.12	NA	136.74
Regeneron Pharmaceuticals, Inc.	19.27	19.27	1.17	45.03	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.24	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
United Therapeutics Corporation	Buy	$16.2B	103.67%	15.92	40.31%
Regeneron Pharmaceuticals, Inc.	Buy	$86.6B	105.58%	19.27	33.61%
Biontech Se	Buy	$28.0B	240.97%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$33.0B	111.58%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$122.1B	113.34%	32.84	-4.51%

About United Therapeutics

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Organization	United Therapeutics
Employees	1168
CEO	Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Industry	Health Technology

Management People of United Therapeutics

Name	Title
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO
Mr. Michael I. Benkowitz	President & COO
Mr. James C. Edgemond	CFO & Treasurer
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary
Mr. Dewey Steadman C.F.A.	Head of Investor Relations
Ms. Holly Hobson	Associate Vice President of Human Resources
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics
Mr. Patrick Poisson	Executive VP of Technical Operations
Dr. Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation
Mr. Gil Golden	Senior VP & Chief Medical Officer

Important FAQs about investing in United Therapeutics from India :

What is United Therapeutics share price today?

United Therapeutics (UTHR) share price today is $362.16.

Can Indians buy United Therapeutics shares?

Yes, Indians can invest in the United Therapeutics (UTHR) from India.

With INDmoney, you can buy United Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy United Therapeutics at zero transaction cost.

How can I buy United Therapeutics shares from India?

It is very easy to buy United Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of United Therapeutics be purchased?

Yes, you can buy fractional shares of United Therapeutics with INDmoney app.

What are the documents required to start investing in United Therapeutics stocks?

To start investing in United Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.